Substituted indole compounds useful as TLR inhibitors

US11878975B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Alaric J. Dyckman · Lawrenceville, US
• Dharmpal S. Dodd · Princeton, US
• Christopher P. Mussari · Princeton, US
• John L. Gilmore · Yardley, US
• Tasir Shamsul Haque · Yardley, US
• Trevor C. Sherwood · Plainsboro, US
• Brian K. Whiteley · Lebanon, US
• Shoshana L. Posy · Highland Park, US
• Sreekantha Ratna Kumar · Bengaluru, IN
• Laxman Pasunoori · Warangal, IN
• Srinivasan Kunchithapatham Duraisamy · Hosur, IN
• Subramanya Hegde · Kanchinakote, IN
• Rushith Kumar Anumula · Secunderabad, IN
• Pitani Veera Venkata Srinivas · Polavaram, IN

Key dates

• Filing date: Dec 18, 2018
• Grant date: Jan 23, 2024
• Expiry date: Dec 18, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.